Bluejay Diagnostics (NASDAQ:BJDX) Major Shareholder Sells $48,913.20 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt sold 34,938 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the transaction, the insider owned 92,055 shares in the company, valued at $128,877. This represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 9th, Financial Lp Hrt acquired 64,047 shares of Bluejay Diagnostics stock. The shares were bought at an average cost of $1.51 per share, with a total value of $96,710.97.

Bluejay Diagnostics Trading Up 8.0%

NASDAQ BJDX opened at $1.35 on Thursday. The stock has a 50-day simple moving average of $2.66 and a 200 day simple moving average of $2.46. The company has a market capitalization of $1.39 million, a PE ratio of -0.12 and a beta of 0.88. Bluejay Diagnostics, Inc. has a 12 month low of $1.03 and a 12 month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last released its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bluejay Diagnostics presently has an average rating of “Sell”.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.